Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
CHRNA9 antibody - N-terminal region
Rabbit Polyclonal Antibody
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB |
|---|---|
| Primary Accession | Q9UGM1 |
| Other Accession | NM_017581, NP_060051 |
| Reactivity | Mouse, Rabbit, Horse, Bovine, Guinea Pig, Dog |
| Predicted | Mouse, Rabbit, Horse, Bovine, Guinea Pig, Dog |
| Host | Rabbit |
| Clonality | Polyclonal |
| Calculated MW | 55kDa |
| Gene ID | 55584 |
|---|---|
| Alias Symbol | NACHRA9, HSA243342 |
| Other Names | Neuronal acetylcholine receptor subunit alpha-9, Nicotinic acetylcholine receptor subunit alpha-9, NACHR alpha-9, CHRNA9, NACHRA9 |
| Format | Liquid. Purified antibody supplied in 1x PBS buffer with 0.09% (w/v) sodium azide and 2% sucrose. |
| Reconstitution & Storage | Add 50 ul of distilled water. Final anti-CHRNA9 antibody concentration is 1 mg/ml in PBS buffer with 2% sucrose. For longer periods of storage, store at 20°C. Avoid repeat freeze-thaw cycles. |
| Precautions | CHRNA9 antibody - N-terminal region is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | CHRNA9 |
|---|---|
| Synonyms | NACHRA9 |
| Function | Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding induces a conformation change that leads to the opening of an ion-conducting channel across the plasma membrane (PubMed:11752216, PubMed:25282151). The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane (PubMed:11752216, PubMed:25282151). In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma. May also regulate keratinocyte adhesion (PubMed:11021840). |
| Cellular Location | Postsynaptic cell membrane; Multi- pass membrane protein. Cell membrane; Multi-pass membrane protein |
| Tissue Location | Expressed in cochlea, keratinocytes, pituitary gland, B-cells and T-cells. |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding induces a conformation change that leads to the opening of an ion-conducting channel across the plasma membrane (PubMed:11752216, PubMed:25282151). The channel is permeable to a range of divalent cations including calcium, the influx of which may activate a potassium current which hyperpolarizes the cell membrane (PubMed:11752216, PubMed:25282151). In the ear, this may lead to a reduction in basilar membrane motion, altering the activity of auditory nerve fibers and reducing the range of dynamic hearing. This may protect against acoustic trauma. May also regulate keratinocyte adhesion (PubMed:11021840).
References
Sgard F.,et al.Mol. Pharmacol. 61:150-159(2002).
Lustig L.R.,et al.Cytogenet. Genome Res. 98:154-159(2002).
Hillier L.W.,et al.Nature 434:724-731(2005).
Nguyen V.T.,et al.Am. J. Pathol. 157:1377-1391(2000).
Peng H.,et al.Life Sci. 76:263-280(2004).
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
